Some pharmaceutical companies appear to collect the "after-effects", the future industry or re-open the talent competition

"Pharmaceutical Network Industry Dynamics" at the end of August, the third batch of drug collection results, a total of 55 varieties of successful procurement, the number of drug varieties close to the first two batches of the total, the average price reduction of selected products 53%, to a high decline of 95%.
with the development of the third batch of collection, which means that the normalization of drug collection began.
background, the pharmaceutical industry is undergoing tremendous changes.
xu is smelling the smell of "changing days", some pharmaceutical executives recently frequently leave the tide.
, China Biopharmaceutical Founder, announced his resignation and was transferred to senior vice chairman of the company's board of directors.
will remain as an Executive Director of the Company, as well as as a member of the Executive Committee and the Nomination Committee.
board of directors also announced that Li Yi had been appointed as an Executive Director and CEO of the Company.
first half of 2020, China Biopharmaceuticals reported revenues of Rmb12.65bn, up 1 per cent year-on-year, while net profit attributable to parents was Rmb1.21bn, down 16 per cent year-on-year.
was included in the collection of products revenue, in the first half of the year, China's biopharmaceutical liver disease products achieved revenue of 2.25 billion yuan, down 31.7% YoY, accounting for 17.8% of total revenue, weak growth;
as to the reasons for the decline, China Biopharma explained that during the reporting period, the negotiated national health insurance catalogue prices began to fall into place and the national volume procurement had a greater impact on the Group's revenue and profits.
In addition, the number of non-emergency visits to hospitals has been significantly reduced, and even many departments have been temporarily closed, and isolation measures have completely disrupted almost all on-site forms of academic activity and doctor communication, with a significant negative impact on drug sales.
understood that in the third batch of mining, China Biopharmaceuticals also has a number of varieties of winning bids, and the decline is obvious.
the new CEO, how to deal with the normalization or larger challenges.
Henrui Pharmaceuticals four deputy general managers resigned collectively Hengrui Pharmaceuticals Board of Directors announced recently, received the company's deputy general manager Jiang Xinhua, Sun Hui, Liu Jie, Mr. Li Kejian resignation report.
all four deputy general managers applied for resignation on the same age.
four vice-presidents resigned en masse just after the end of their terms on the new board of directors, which seemed strange to many.
, Hengrui Pharmaceuticals market value of 500 billion yuan, some netizens pointed out that these executive departures are "convenient to reduce their holdings."
too much trouble to reduce their holdings.
understood that the four resigned vice-presidents, each holding more than 170 million shares of the company, four people hold a total of 7.597 million shares of Hengrui Pharmaceuticals shares.
2020 half-year report, the company achieved revenue of RMB11,309 million, up 12.79% YoY, while net profit attributable to shareholders of listed companies was RMB2,662 million, up 10.34% YoY.
Hengrui Pharmaceutical's main anti-tumor, surgical anesthesia, copicides and integrated four product lines.
first half of this year, its anaesthetic line revenue declined from the same period last year, contrast agent and integrated line revenue was basically the same as in the first half of last year;
It is understood that its anaesthetic line revenue decline factors related to the collection, in 2018, Hengrui Pharmaceutical's anaesthetic line key varieties of hydrochloric acid right metomide was included in the first batch of "4 plus 7" collection, but due to the suspension of the evaluation of no bid.
nearly two years, Hengrui Pharmaceuticals right Metomede's market share has gradually been eroded.
"4 plus 7" set of expansion, Hengrui Medicine only 1 variety of Ebershatan won the bid, the second batch of drug collection, Hengrui Pharmaceutical acetic acid abitron, tiggio capsules, hydrochloric acid quretaquine slow release tablets, albumin yew alcohol 4 varieties won the bid, the average price reduction of more than 70%.
And in the recently concluded third batch of national harvesting, Hengrui Pharmaceutical's ammonia bromoso, Tan live new, Celexibu, non-busta, capertabin, to curvature 6 varieties were included in the collection list, the results of the harvest of 4 varieties to be selected.
Industry believes that volume procurement is creating considerable pressure on the company's generics business, but Hengrui is now in the transition phase from copy-based to innovation-driven, followed by an increase in the proportion of innovative drugs, or no longer worry about the impact of harvesting.
The future wave of pharmaceutical executive departures or continued in addition to these two pharmaceutical companies, there is GlaxoSmithKline GSK vice president, head of the respiratory business, Wang Hong left, Kangya Pharmaceuticals He Zhongxuan resigned as general manager ... The industry believes that in the future there will be a number of pharmaceutical executives to leave, the pharmaceutical industry is particularly affected by the policy, many pharmaceutical companies must find a way to transform, or they will be eliminated.
people believe that in the pharmaceutical industry, the adjustment of talent has been the fundamental to the future survival of pharmaceutical companies.
the background of the whole industry transformation, the major pharmaceutical companies should re-establish their own talent system, eliminate some people who do not have professional ability, and match the current stage of development of suitable talent.
, with the landing of various reform policies, the future of the core executive turnover will also emerge, the industry will start a talent war.